<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905333</url>
  </required_header>
  <id_info>
    <org_study_id>D2452L00021</org_study_id>
    <secondary_id>IMPACT 15381</secondary_id>
    <nct_id>NCT00905333</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal</brief_title>
  <official_title>Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scentryphar Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cori Analyticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LabClin Laboratório Clínico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratório de Patologia Clínica Dr. Franceschi Ltda.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculdade de Ciências Farmacêuticas de Ribeirão Preto - Centro de Bioequivalência</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations
      of candesartan and felodipine in a combination package comparing with the fasting intake of
      commercial formulations of both Atacand ® and Splendil®
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetic interaction evaluation of two test formulations of 16 mg of candesartan and 5 mg of felodipine after a fasting period and the comparison with the intake of both reference medicaments: Atacand® and Splendil®.</measure>
    <time_frame>76 blood samples per subject</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan (test)</intervention_name>
    <description>16 mg oral tablet, single dose</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felodipine (test)</intervention_name>
    <description>5 mg oral extended release tablet, single dose</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>16 mg oral tablet, single dose</description>
    <arm_group_label>Single-arm</arm_group_label>
    <other_name>Atacand®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felodipine</intervention_name>
    <description>5 mg oral extended release tablet, single dose</description>
    <arm_group_label>Single-arm</arm_group_label>
    <other_name>Splendil®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  BMI &gt; or = 19 and &lt; or = 28 (Dietary Guidelines Advisory Committee, 2005)

        Exclusion Criteria:

          -  Not healthy

          -  Chronic drug intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Abib Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scentryphar Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moises L. P Vanuncci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Scentryphar Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itatiba</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Americana</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <last_update_submitted>December 6, 2010</last_update_submitted>
  <last_update_submitted_qc>December 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>candesartan</keyword>
  <keyword>felodipine</keyword>
  <keyword>test formulations</keyword>
  <keyword>Atacand®</keyword>
  <keyword>Splendil®</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>blood samples</keyword>
  <keyword>after meal intake interaction</keyword>
  <keyword>Kinetic interaction amongst test formulations of Candesartan and Felodipine and the brands Atacand® and Splendil® in healthy volunteers after a fasting period.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

